Pfizer CentreOne Header Pfizer CentreOne Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Panaxia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Panaxia's Agreement with International Pharma Neuraxpharm is Finalized","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Permira Funds","pharmaFlowCategory":"D","amount":"$1,880.0 million","upfrontCash":"Undisclosed","newsHeadline":"Permira Funds to Acquire Leading European CNS Specialty Pharmaceutical Company Neuraxpharm","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Undisclosed","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Brain Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Expands Its Business in Southeast Europe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Reinforces Presence in Poland with The Acquisition of Glenmark\u2019s CNS Product Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Acquires Market-Leading Buccolam\u00ae For Emergency Treatment of Epileptic Children","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Panaxia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Enters the Advanced Medical Cannabis Market in Germany with A Collaboration with Panaxia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Expands Italian Product Portfolio with A Well-Established Brand From Almirall","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraxpharm Launches First Product in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm to Increase Branded Business Through Upcoming Acquisition of Established Products from Sanofi","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Announces Closing of Acquisition of Established Products from Sanofi","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","amount":"$645.0 million","upfrontCash":"$140.0 million","newsHeadline":"TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI\u00ae (ublituximab-xiiy)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Large molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Neuraxpharm

    Menu

    Neuraxpharm

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Neuraxpharm

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)

              Details:

              Under the agreement, TG Therapeutics will commercialise Briumvi (ublituximab), the first and only anti-CD20 monoclonal antibody approved in the United States and European Union for adult patients with relapsing forms of multiple sclerosis.

              Lead Product(s): Ublituximab-xiiy

              Therapeutic Area: Neurology Product Name: Briumvi

              Highest Development Status: Approved Product Type: Large molecule

              Recipient: TG Therapeutics

              Deal Size: $645.0 million Upfront Cash: $140.0 million

              Deal Type: Licensing Agreement August 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neuraxpharm

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Neuraxpharm Announces Closing of Acquisition of Established Products from Sanofi

              Details:

              The acquisition will strengthen Neuraxpharm's position as a leading company focused on CNS by including 2 product portfolios for CNS disorders, pain and vascular diseases. The CNS portfolio includes Nozinan (levomepromazine maleate), Tranxene, Tiapridal, Dogmatil, Largactil.

              Lead Product(s): Levomepromazine

              Therapeutic Area: Psychiatry/Psychology Product Name: Nozinan

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Sanofi

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition February 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neuraxpharm

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Neuraxpharm to Increase Branded Business Through Upcoming Acquisition of Established Products from Sanofi

              Details:

              Nozinan (levomepromazine) is a neuroleptic with indications in psychiatry and general medicine, particularly in terminal illness. Clinically it is more sedative and more potent than chlorpromazine in management of psychotic conditions and in relief of severe chronic pain.

              Lead Product(s): Levomepromazine

              Therapeutic Area: Psychiatry/Psychology Product Name: Nozinan

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Sanofi

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition July 12, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neuraxpharm

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Neuraxpharm Expands Its Business in Southeast Europe

              Details:

              Having acquired Brain Therapeutics, Neuraxpharm is now able to bring new products to the Greek market including the market-leading product for emergency treatment of children and adolescents with epilepsy, Buccolam®, will be among the products to be offered.

              Lead Product(s): Midazolam

              Therapeutic Area: Neurology Product Name: Buccolam

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Brain Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition March 08, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neuraxpharm

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Neuraxpharm Launches First Product in Japan

              Details:

              Buccolam (oromucosal midazolam), value-added buccal midazolam indicated for emergency treatment of children and adolescents from 3 months to 18 years with epilepsy suffering from prolonged acute convulsive seizures.

              Lead Product(s): Midazolam

              Therapeutic Area: Neurology Product Name: Buccolam

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Takeda Pharmaceutical

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neuraxpharm

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Permira Funds to Acquire Leading European CNS Specialty Pharmaceutical Company Neuraxpharm

              Details:

              The Permira funds will support the management’s vision of becoming the leading CNS-focused specialty pharmaceutical platform in Europe through driving the commercialization of Neuraxpharm’s attractive new product pipeline and support further its expansion internationally.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Permira Funds

              Deal Size: $1,880.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition September 22, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neuraxpharm

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Neuraxpharm Acquires Market-Leading Buccolam® For Emergency Treatment of Epileptic Children

              Details:

              Buccolam® (Midazolam), fits perfectly within Neuraxpharm’s portfolio, strengthening its position as the European CNS specialist in several European countries, and offers the opportunity to expand the commercial footprint, including into the Nordics and Ireland.

              Lead Product(s): Midazolam

              Therapeutic Area: Neurology Product Name: Buccolam

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Takeda Pharmaceutical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition September 14, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neuraxpharm

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Panaxia's Agreement with International Pharma Neuraxpharm is Finalized

              Details:

              The agreement, which anchors a previous MOU entered by the companies, includes exclusivity for Panaxia products, as well as an option for scaling the distribution to additional countries, also including further major European countries.

              Lead Product(s): Cannabis products

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Panaxia

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement July 22, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neuraxpharm

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Neuraxpharm Expands Italian Product Portfolio with A Well-Established Brand From Almirall

              Details:

              Ansiolin® (diazepam) is a benzodiazepine indicated to treat anxiety and other somatic or psychiatric conditions associated to anxiety syndrome, while it is also indicated for insomnia.

              Lead Product(s): Diazepam

              Therapeutic Area: Psychiatry/Psychology Product Name: Ansiolin

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Almirall

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition June 26, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neuraxpharm

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Neuraxpharm Enters the Advanced Medical Cannabis Market in Germany with A Collaboration with Panaxia

              Details:

              The establishment of the business collaboration reflects Neuraxpharm’s and Panaxia’s strategy to become a European leader in the commercialization of medical cannabis products.

              Lead Product(s): Cannabis-based Product

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Recipient: Panaxia

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Evonik
              AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
              Post Enquiry
              POST ENQUIRY